和胃方Ⅱ号治疗糖尿病性胃肠病的临床研究

Clinical Study of Using Hewei Decoction-Ⅱ Combined with Mosapride to Treat Diabetic Gastrointestinal Disorder

目的:观察和胃方Ⅱ号联合莫沙必利治疗糖尿病性胃肠病的临床疗效和复发率。方法:将80例符合标准的患者随机分为治疗组和对照组各40例。在糖尿病一般治疗的基础上,治疗组给予口服自拟中药和胃方Ⅱ号及莫沙必利,对照组仅给予莫沙必利,疗程4周,两组在服药期间均禁止服用其它治疗胃病的药物及影响疗效观察的药物,对两种疗法进行对比,计算各组临床有效率及评价胃固体半排空时间的改善情况;治疗结束后随访8周,观察患者有无病情复发。结果:两组症状较治疗前均改善(P<0.05),胃固体排空速度均加快(P<0.05)。治疗组胃肠病症状改善率明显优于对照组(P<0.05);治疗组胃排空速度改善明显优于对照组(P<0.01);治疗组复发率明显低于对照组(P<0.05)。结论:和胃方Ⅱ号联合莫沙必利可有效改善胃肠病症状,提高胃排空速度,减少复发率,效果优于单用传统促动力药莫沙必利。

Objective： To observe the clinical therapeutic effects and rate of recurrence of using Hewei Decoction-Ⅱ com- bined with mosapride to treat diabetic gastrointestinal disorder （DGID）. Methods ： 80 patients met the diagnostic criteria were randomly divided into treatment group and controlled group, n = 40 cases. The treatment group was treated with Hewei Decoction - Ⅱ combined with mosapride, while the controlled group was treated with mosapride only, two groups were 4 weeks as 1 course. No other kinds of stomach medicine were allowed to take during the process. And then compared the two kinds of treatments. Each group was calculated its clinical efficacy and evaluated the improvement of changes in 13C-octanoic acid breath test. After 8 weeks, observing the recurrence of treatment. Results ： Symptoms of both groups were improved （P 〈0. 05 ）. Gastric empty- ing rate were both accelerated （P 〈0. 05 ）. Gastrointestinal symptoms of the treatment group improved significantly better than the controlled group （P 〈0. 05）. Gastric emptying rate of the treatment group improved significantly better than the controlled group （P 〈0. 01 ）. The recurrence rate of the treatment group was lower than the controlled group （ P 〈0. 05）. Conclusion ： Hewei Decoction- Ⅱ combined with mosapride is more effective to improve gastrointestinal symptoms, gastric emptying time and reduce the recurrence rate than using mosapride only.